Guido Oelkers

Guido Oelkers currently works at BSN medical International Holding GmbH & Co. KG, as Chief Executive Officer & Director, Swedish Orphan Biovitrum AB, as President & Chief Executive Officer from 2017, Sobi US Holding Corp., as President & Chief Executive Officer, Nanolive SA, as Chairman, Dova Pharmaceuticals, Inc., as Director from 2019, and Swedish Orphan Biovitrum, Inc., as Director.
Dr. Oelkers also formerly worked at Gambro AB, as President & Chief Executive Officer from 2011 to 2013, Invida Group Pte Ltd., as Chief Executive Officer, BSN medical GmbH, as Group Chief Executive Officer, Gambro Lundia AB, as President & Chief Executive Officer, BSN Medical Holding, as Chief Executive Officer from 2014 to 2017, BSN medical BV, as Chief Executive Officer, Meda AB, as Director in 2014, Takeda Pharmaceuticals International AG, as EVP & Director-Commercial Operations from 2008 to 2010, Sartorius AG, as Member-Supervisory Board, Aventis Pharma Deutschland GmbH, as Principal, Nycomed AB, as EVP-Commercial Operations, and Takeda A, as Executive Vice President-Commercial Operations.
Dr. Oelkers received his doctorate degree from the University of South Australia and graduate degree from London South Bank University.